Design of a Tumor Binding GMCSF as Intratumoral Immunotherapy of Solid Tumors
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.2c00897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Aparna Raghavachar Chakravarti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bioengineering Program, The University of Kansas, Lawrence, Kansas 66045, United States. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Philanthropic Educational Organization, National Heart, Lung, and Blood Institute, American Association of University Women.
Abstract (Originalsprache)
Next-generation cancer immunotherapies may utilize immunostimulants to selectively activate the host immune system against tumor cells. Checkpoint inhibitors (CPIs) like anti-PD1/PDL-1 that inhibit immunosuppression have shown unprecedented success but are only effective in the 20-30% of patients that possess an already "hot" (immunogenic) tumor. In this regard, intratumoral (IT) injection of immunostimulants is a promising approach since they can work synergistically with CPIs to overcome the resistance to immunotherapies by inducing immune stimulation in the tumor. One such immunostimulant is granulocyte macrophage-colony-stimulating factor (GMCSF) that functions by recruiting and activating antigen-presenting cells (dendritic cells) in the tumor, thereby initiating anti-tumor immune responses. However, key problems with GMCSF are lack of efficacy and the risk of systemic toxicity caused by the leakage of GMCSF from the tumor tissue. We have designed tumor-retentive versions of GMCSF that are safe yet potent immunostimulants for the local treatment of solid tumors. The engineered GMCSFs (eGMCSF) were synthesized by recombinantly fusing tumor-ECM (extracellular matrix) binding peptides to GMCSF. The eGMCSFs exhibited enhanced tumor binding and potent immunological activity in vitro and in vivo. Upon IT administration, the tumor-retentive eGMCSFs persisted in the tumor, thereby alleviating systemic toxicity, and elicited localized immune activation to effectively turn an unresponsive immunologically "cold" tumor "hot".
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bioengineering Program, The University of Kansas, Lawrence, Kansas 66045, United States.
- HylaPharm, LLC, Lawrence, Kansas 66047, United States.
- Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas 66047, United States.
- Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, Kansas 66045, United States.
ORCID-Profile: Aparna Raghavachar Chakravarti, Marcus Laird Forrest, Cory J Berkland
Förderung
- Philanthropic Educational Organization
- National Heart, Lung, and Blood Institute
- American Association of University Women
Zitieren
APA
Chakravarti, A. R., Groer, C. E., Gong, H., Yudistyra, V., Forrest, M. L., & Berkland, C. J. (2023). Design of a Tumor Binding GMCSF as Intratumoral Immunotherapy of Solid Tumors. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.2c00897
Vancouver
Chakravarti AR, Groer CE, Gong H, Yudistyra V, Forrest ML, Berkland CJ. Design of a Tumor Binding GMCSF as Intratumoral Immunotherapy of Solid Tumors. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.2c00897
BibTeX
@article{Chakravarti2023,
author = {Chakravarti, Aparna Raghavachar and Groer, Chad E and Gong, Huan and Yudistyra, Vivian and Forrest, Marcus Laird and Berkland, Cory J},
title = {Design of a Tumor Binding GMCSF as Intratumoral Immunotherapy of Solid Tumors},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.2c00897}
}
EUVIMED